Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48

Benzinga Newsdesk www.benzinga.com Neutral 72.1%

Neg 0% Neu 72.1% Pos 0%

Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $48.